Dr Reddys Laboratories Stock Fundamentals

RDY Stock  USD 75.49  0.25  0.33%   
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDY Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
At this time, Dr Reddys' Other Operating Expenses is fairly stable compared to the past year. EBIT is likely to rise to about 116.3 B in 2024, whereas Cost Of Revenue is likely to drop slightly above 44.3 B in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RDY Working Capital Analysis

Dr Reddys' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
 2021 2022 2023 2024 (projected)
Other Current Liabilities41.6B48.9B56.2B59.0B
Total Assets296.7B322.9B371.3B206.1B

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Dr Reddys Working Capital

    
  118.53 B  
Most of Dr Reddys' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

RDY Capital Surpluse

Capital Surpluse

7.09 Billion

At this time, Dr Reddys' Capital Surpluse is fairly stable compared to the past year.
Based on the company's disclosures, Dr Reddys Laboratories has a Working Capital of 118.53 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is significantly lower than that of the firm.

Dr Reddys Laboratories Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Dr Reddys's current stock value. Our valuation model uses many indicators to compare Dr Reddys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dr Reddys competition to find correlations between indicators driving Dr Reddys's intrinsic value. More Info.
Dr Reddys Laboratories is rated below average in price to sales category among related companies. It is currently regarded as top stock in current liabilities category among related companies creating about  20,899,357,602  of Current Liabilities per Price To Sales. Total Current Liabilities is likely to drop to about 68.3 B in 2024. Non Current Liabilities Total is likely to drop to about 4.7 B in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Dr Reddys by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Dr Reddys' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dr Reddys' earnings, one of the primary drivers of an investment's value.

RDY Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.
Dr Reddys is currently under evaluation in total asset category among related companies.

Dr Reddys Institutional Holders

Institutional Holdings refers to the ownership stake in Dr Reddys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dr Reddys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dr Reddys' value.
Shares
Gqg Partners Llc2023-12-31
437 K
Ameriprise Financial Inc2023-09-30
434.5 K
Millennium Management Llc2023-09-30
361.6 K
Grantham, Mayo, Van Otterloo & Co., Llc2023-12-31
329.1 K
Lazard Asset Management Llc2023-09-30
306.1 K
Acadian Asset Management Llc2023-09-30
270.3 K
Schroder Investment Management Group2023-12-31
266.7 K
Mondrian Investment Partners Ltd2023-09-30
216.1 K
Assenagon Asset Management Sa2023-12-31
196.1 K
Blackrock Inc2023-12-31
M
Royal Bank Of Canada2023-09-30
2.1 M

RDY Fundamentals

About Dr Reddys Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Current Deferred Revenue1.8 B1.7 B
Total Revenue282.8 B296.9 B
Cost Of Revenue49.3 B44.3 B
Ebit Per Revenue 0.35  0.37 

Currently Active Assets on Macroaxis

When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:
Check out Dr Reddys Piotroski F Score and Dr Reddys Altman Z Score analysis.
Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for RDY Stock analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bonds Directory
Find actively traded corporate debentures issued by US companies
Fundamental Analysis
View fundamental data based on most recent published financial statements
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.103
Dividend Share
40
Earnings Share
3.78
Revenue Per Share
272.4618
Quarterly Revenue Growth
0.066
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.